Continued Access to RXDX-105
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
Non Small Cell Lung Cancer|Ovarian Cancer|RET Gene Mutation|BRAF Gene Mutation
DRUG: RXDX-105
Evaluation during treatment/intervention, Safety assessments will be performed as standard of care and as clinically indicated. This will include monitoring of adverse events, including serious adverse events including CTCAE grading., Through study completion, up to five years.
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.